Attention Site Visitor

You are currently visiting the UI Health Care Clinical Trials website on a version of the web browser: Internet Explorer. Internet Explorer is no longer being supported by Microsoft, and there are features and functionality on this website that does not operate properly when using Internet Explorer. If you have an alternative browser, such as: Microsoft Edge, Google Chrome, Mozilla Firefox, or Apple Safari, we suggest you switch to that browser for the optimal viewing experience.

Thank you

GOG-3087/NXP800 (Part B)

Holden Comprehensive Cancer Center

Cancer Gynecology Adult Subjects Female Subjects

Overview

Part A of the study is a dose escalation by cohort study of NXP800 administered to patients with advanced cancers. The study will identify the maximum tolerated dose (MTD) and propose dose and dose schedules for future studies.

In Part B doses selected in Part A are administered to patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.

Principal investigator

David Bender

Obstetrics/Gynecology

View other research studies by David Bender

Participate in this trial

Are you interested in enrolling in this study? Learn more here.

I'm Interested In Participating

Details

IRB Number

202312064

NCT Number

NCT

Study Status

Open

Currently Recruiting

Yes

Study Type

Interventional

Cancer Study

Yes

Compensation Available

Yes